Copyright Reports & Markets. All rights reserved.

Global Sacituzumab Tirumotecan Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Sacituzumab Tirumotecan Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Monoclonal Antibody, mAb
    • 1.3.3 Bispecific Antibody, bsAb
  • 1.4 Market Analysis by Specification
    • 1.4.1 Overview: Global Sacituzumab Tirumotecan Consumption Value by Specification: 2021 Versus 2025 Versus 2032
    • 1.4.2 60 mg/vial
    • 1.4.3 120 mg/vial
  • 1.5 Market Analysis by Production Technology
    • 1.5.1 Overview: Global Sacituzumab Tirumotecan Consumption Value by Production Technology: 2021 Versus 2025 Versus 2032
    • 1.5.2 Innovator
    • 1.5.3 Generic
  • 1.6 Market Analysis by Dosage Form
    • 1.6.1 Overview: Global Sacituzumab Tirumotecan Consumption Value by Dosage Form: 2021 Versus 2025 Versus 2032
    • 1.6.2 Lyophilized Powder for Injection
    • 1.6.3 Injection Solution
  • 1.7 Market Analysis by Application
    • 1.7.1 Overview: Global Sacituzumab Tirumotecan Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.7.2 Breast Cancer
    • 1.7.3 Lung Cancer
    • 1.7.4 Digestive System Tumors
    • 1.7.5 Others
  • 1.8 Global Sacituzumab Tirumotecan Market Size & Forecast
    • 1.8.1 Global Sacituzumab Tirumotecan Consumption Value (2021 & 2025 & 2032)
    • 1.8.2 Global Sacituzumab Tirumotecan Sales Quantity (2021-2032)
    • 1.8.3 Global Sacituzumab Tirumotecan Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Kelun-Biotech
    • 2.1.1 Kelun-Biotech Details
    • 2.1.2 Kelun-Biotech Major Business
    • 2.1.3 Kelun-Biotech Sacituzumab Tirumotecan Product and Services
    • 2.1.4 Kelun-Biotech Sacituzumab Tirumotecan Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Kelun-Biotech Recent Developments/Updates
  • 2.2 Merck & Co
    • 2.2.1 Merck & Co Details
    • 2.2.2 Merck & Co Major Business
    • 2.2.3 Merck & Co Sacituzumab Tirumotecan Product and Services
    • 2.2.4 Merck & Co Sacituzumab Tirumotecan Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Merck & Co Recent Developments/Updates
  • 2.3 Sichuan Kelun Pharmaceutical
    • 2.3.1 Sichuan Kelun Pharmaceutical Details
    • 2.3.2 Sichuan Kelun Pharmaceutical Major Business
    • 2.3.3 Sichuan Kelun Pharmaceutical Sacituzumab Tirumotecan Product and Services
    • 2.3.4 Sichuan Kelun Pharmaceutical Sacituzumab Tirumotecan Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Sichuan Kelun Pharmaceutical Recent Developments/Updates

3 Competitive Environment: Sacituzumab Tirumotecan by Manufacturer

  • 3.1 Global Sacituzumab Tirumotecan Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Sacituzumab Tirumotecan Revenue by Manufacturer (2021-2026)
  • 3.3 Global Sacituzumab Tirumotecan Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Sacituzumab Tirumotecan by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Sacituzumab Tirumotecan Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Sacituzumab Tirumotecan Manufacturer Market Share in 2025
  • 3.5 Sacituzumab Tirumotecan Market: Overall Company Footprint Analysis
    • 3.5.1 Sacituzumab Tirumotecan Market: Region Footprint
    • 3.5.2 Sacituzumab Tirumotecan Market: Company Product Type Footprint
    • 3.5.3 Sacituzumab Tirumotecan Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Sacituzumab Tirumotecan Market Size by Region
    • 4.1.1 Global Sacituzumab Tirumotecan Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Sacituzumab Tirumotecan Consumption Value by Region (2021-2032)
    • 4.1.3 Global Sacituzumab Tirumotecan Average Price by Region (2021-2032)
  • 4.2 North America Sacituzumab Tirumotecan Consumption Value (2021-2032)
  • 4.3 Europe Sacituzumab Tirumotecan Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Sacituzumab Tirumotecan Consumption Value (2021-2032)
  • 4.5 South America Sacituzumab Tirumotecan Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Sacituzumab Tirumotecan Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Sacituzumab Tirumotecan Sales Quantity by Type (2021-2032)
  • 5.2 Global Sacituzumab Tirumotecan Consumption Value by Type (2021-2032)
  • 5.3 Global Sacituzumab Tirumotecan Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Sacituzumab Tirumotecan Sales Quantity by Application (2021-2032)
  • 6.2 Global Sacituzumab Tirumotecan Consumption Value by Application (2021-2032)
  • 6.3 Global Sacituzumab Tirumotecan Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Sacituzumab Tirumotecan Sales Quantity by Type (2021-2032)
  • 7.2 North America Sacituzumab Tirumotecan Sales Quantity by Application (2021-2032)
  • 7.3 North America Sacituzumab Tirumotecan Market Size by Country
    • 7.3.1 North America Sacituzumab Tirumotecan Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Sacituzumab Tirumotecan Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Sacituzumab Tirumotecan Sales Quantity by Type (2021-2032)
  • 8.2 Europe Sacituzumab Tirumotecan Sales Quantity by Application (2021-2032)
  • 8.3 Europe Sacituzumab Tirumotecan Market Size by Country
    • 8.3.1 Europe Sacituzumab Tirumotecan Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Sacituzumab Tirumotecan Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Sacituzumab Tirumotecan Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Sacituzumab Tirumotecan Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Sacituzumab Tirumotecan Market Size by Region
    • 9.3.1 Asia-Pacific Sacituzumab Tirumotecan Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Sacituzumab Tirumotecan Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Sacituzumab Tirumotecan Sales Quantity by Type (2021-2032)
  • 10.2 South America Sacituzumab Tirumotecan Sales Quantity by Application (2021-2032)
  • 10.3 South America Sacituzumab Tirumotecan Market Size by Country
    • 10.3.1 South America Sacituzumab Tirumotecan Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Sacituzumab Tirumotecan Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Sacituzumab Tirumotecan Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Sacituzumab Tirumotecan Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Sacituzumab Tirumotecan Market Size by Country
    • 11.3.1 Middle East & Africa Sacituzumab Tirumotecan Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Sacituzumab Tirumotecan Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Sacituzumab Tirumotecan Market Drivers
  • 12.2 Sacituzumab Tirumotecan Market Restraints
  • 12.3 Sacituzumab Tirumotecan Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Sacituzumab Tirumotecan and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Sacituzumab Tirumotecan
  • 13.3 Sacituzumab Tirumotecan Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Sacituzumab Tirumotecan Typical Distributors
  • 14.3 Sacituzumab Tirumotecan Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Sacituzumab Tirumotecan market size was valued at US$ 206 million in 2025 and is forecast to a readjusted size of US$ 936 million by 2032 with a CAGR of 16.7% during review period.
    Sacituzumab Tirumotecan is an antibody–drug conjugate (ADC) targeting trophoblast cell-surface antigen 2 (TROP-2). It consists of a humanized monoclonal antibody, a cleavable linker, and a cytotoxic payload. The antibody component specifically recognizes and binds to the TROP-2 antigen expressed on tumor cells, enabling the targeted delivery of the cytotoxic agent into the cells, where the active component is released to inhibit DNA replication and induce cell death. This drug is mainly used for the targeted treatment of various solid tumors, such as breast cancer and lung cancer. It is characterized by high targeting specificity, strong cytotoxic efficacy, and relatively controllable systemic toxicity, making it an important innovative therapy in the field of antibody–drug conjugates.In 2025, global sacituzumab tirumotecan production reached approximately 1.2 million units.
    Sacituzumab Tirumotecan, as a TROP-2-targeting antibody–drug conjugate (ADC), is in a rapid growth phase within the precision oncology market. With the rising incidence of high-prevalence solid tumors such as breast cancer and lung cancer, along with the increasing demand for targeted therapies, this drug is gradually gaining clinical recognition and driving market expansion due to its advantages of “high targeting specificity and potent cytotoxicity.” Meanwhile, the maturation of ADC technology platforms and supportive policies for innovative drugs have also facilitated its commercialization. However, market competition is intensifying, including from products with the same target (such as Trodelvy) as well as other ADC drugs (such as Enhertu), which pose direct competitive pressure. Overall, the market for Sacituzumab Tirumotecan represents a “high-value, fast-growing” segment of innovative therapeutics, with future growth mainly driven by indication expansion, global market development, and continuous validation of clinical data.
    This report is a detailed and comprehensive analysis for global Sacituzumab Tirumotecan market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Sacituzumab Tirumotecan market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
    Global Sacituzumab Tirumotecan market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
    Global Sacituzumab Tirumotecan market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
    Global Sacituzumab Tirumotecan market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Sacituzumab Tirumotecan
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Sacituzumab Tirumotecan market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Kelun-Biotech, Merck & Co, Sichuan Kelun Pharmaceutical, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Sacituzumab Tirumotecan market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Monoclonal Antibody, mAb
    Bispecific Antibody, bsAb
    Market segment by Specification
    60 mg/vial
    120 mg/vial
    Market segment by Production Technology
    Innovator
    Generic
    Market segment by Dosage Form
    Lyophilized Powder for Injection
    Injection Solution
    Market segment by Application
    Breast Cancer
    Lung Cancer
    Digestive System Tumors
    Others
    Major players covered
    Kelun-Biotech
    Merck & Co
    Sichuan Kelun Pharmaceutical
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Sacituzumab Tirumotecan product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Sacituzumab Tirumotecan, with price, sales quantity, revenue, and global market share of Sacituzumab Tirumotecan from 2021 to 2026.
    Chapter 3, the Sacituzumab Tirumotecan competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Sacituzumab Tirumotecan breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Sacituzumab Tirumotecan market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Sacituzumab Tirumotecan.
    Chapter 14 and 15, to describe Sacituzumab Tirumotecan sales channel, distributors, customers, research findings and conclusion.

    Buy now